A dosage regimen of M-receptor blocker after TURP for severe BPH with predominant urine storage symptoms.
- Author:
Jian-Liang CAI
1
;
Da CHEN
1
;
Yu-Feng SONG
2
;
Jing-Chao HAN
1
;
Jing-Tian XIAO
3
;
Ning-Chen LI
4
;
Ming XIA
1
;
Yan-Qun NA
4
Author Information
1. Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
2. No. 3 Department of Surgery, Naimanqi People's Hospital, Tongliao, Inner Mongolia 028000, China.
3. No. 1 Department of Surgery, Kulunqi Hospital, Tongliao, Inner Mongolia 028000, China.
4. Wu Jieping Medical Center of Urology, Peking University, Beijing 100027, China.
- Publication Type:Journal Article
- Keywords:
M-receptor blocker;
transurethral resection of the prostate;
urine storage symptom;
benign prostate hyperplasia
- MeSH:
Administration, Oral;
Clinical Protocols;
Drug Administration Schedule;
Humans;
Male;
Muscarinic Antagonists;
administration & dosage;
Postoperative Care;
Prostatic Hyperplasia;
drug therapy;
surgery;
Quality of Life;
Recurrence;
Tolterodine Tartrate;
administration & dosage;
Transurethral Resection of Prostate;
Treatment Outcome;
Urination;
Urological Agents;
administration & dosage
- From:
National Journal of Andrology
2017;23(9):793-797
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the dosage regimen of oral M-receptor blocker following transurethral resection of the prostate (TURP) for severe benign prostate hyperplasia (BPH) with predominant urine storage period symptoms (USPSs) and its clinical effect.
METHODS:Severe BPH patients with predominant USPSs received oral tolterodine (2 mg q12d or 4 mg qd) 6 hours after TURP for 4 weeks. The medication continued for another 2 weeks in case of recurrence of USPSs or until the 12th week in case of repeated recurrence. Before and at 1, 4, 8 and 12 weeks after TURP, we analyzed the International Prostate Symptoms Score (IPSS), quality of life (QoL) score, maximum urinary flow rate (Qmax), and postvoid residual volume (PVR) of the patients.
RESULTS:Complete clinical data were collected from 106 cases, of which 33 achieved successful drug withdrawal with no aggravation of USPSs at 4 weeks after TURP, 51 at 6－8 weeks, 13 at 10－12 weeks, and 9 needed medication after 12 weeks. Before and at 1, 4, 8 and 12 weeks after TURP, the total IPSSs were 25.33 ± 3.45, 19.33 ± 3.62, 11.56 ± 2.45, 8.38 ± 2.0 and 7.74 ± 1.87, those in the urine storage period were 11.97 ± 1.53, 10.76 ± 1.82, 6.16 ± 1.22, 4.08 ± 1.19 and 3.91 ± 1.15, those at urine voiding were 9.80 ± 1.60, 5.59 ± 1.45, 3.40 ± 0.92, 2.85 ± 0.71, and 2.61 ± 0.67, and the QoL scores were 4.70 ± 0.78, 3.92 ± 0.75, 2.55 ± 0.74, 1.83 ± 0.72 and 1.66 ± 0.75, respectively, with statistically significant differences between the baseline and the scores at 1 and 4 weeks (P <0.01) but not at 8 or 12 weeks (P >0.05). Qmax and PVR were improved progressively and significantly at 1 and 4 weeks (P <0.01) but not at 8 or 12 weeks (P >0.05).
CONCLUSIONS:Four to eight weeks of oral administration of M-receptor blocker may be an effective dosage regimen for severe BPH with predominant USPSs after TURP.
